ISRG

No open position. Record a trade on the Portfolio tab and it flows into this card.

Intuitive Surgical (ISRG) reported strong Q2 and Q1 2026 results with robust revenue growth, a debt-free balance sheet, and significant shareholder returns. The company faces tariff headwinds and competitive pressures. No financial facts were assembled; fundamentals are derived solely from filing summaries.

Generated by deepseek-v4-flash. Advisory only — every flag is logged against the rule that raised it for the review loop.

• 10-QJul 21, 2026

  Source ↗

  Intuitive Surgical delivered strong Q2 2026 results with revenue up 18.5% to $2.9 billion, driven by system placements and procedure growth, and net income rose to $818 million. The company continues to invest aggressively in R&D and manufacturing capacity while returning significant cash to shareholders via buybacks ($1.5 billion in H1). A key strategic move was the acquisition of direct distribution in Italy, Spain, and Portugal for $533 million, which should improve margins long-term. However, the growing risk from US and retaliatory tariffs on imported components (especially from Mexico, Germany, and China) could pressure costs. The $3.4 billion backlog provides visibility, but the operating environment remains uncertain. Investors should monitor tariff developments and the ramp of da Vinci 5 systems, now cleared in Japan and Europe.

  Show extraction ▾Hide extraction ▴

  MD&A highlights

  • ·Total revenue increased 18.5% to $2.9 billion for Q2 2026 from $2.4 billion in Q2 2025.
  • ·Net income attributable to Intuitive Surgical, Inc. was $818.1 million for Q2 2026, compared to $658.4 million for Q2 2025.
  • ·During Q2 2026, the Company repurchased 0.9 million shares for $379.0 million.
  • ·On March 1, 2026, Intuitive acquired the da Vinci and Ion distribution businesses in Italy, Spain, and Portugal for approximately $533.1 million in cash.

  Backlog

  As of June 30, 2026, the transaction price allocated to remaining performance obligations was $3.4 billion, with approximately half expected to be recognized in the next 12 months and the remainder over the term of arrangements, generally up to 5 years.

  Key risks

  • ·Recent tariff changes imposed by the U.S. and other countries have created increased risks and uncertainties regarding future results of operations.
  • ·Macroeconomic and geopolitical factors, including inflation, elevated interest rates, and supply chain disruptions, could materially adversely affect results and liquidity.
  • ·The Company faces competition from alternative surgical approaches and robotic-assisted systems, including domestic competitors in markets like China.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  We expect to continue to invest in our business, including research and development, manufacturing capacity, and commercial infrastructure, to support our long-term growth. However, recent tariff changes and macroeconomic uncertainties pose risks to our future results of operations.

  Strategic priorities

  • ·Advancing minimally invasive care through a comprehensive ecosystem including systems, instruments, learning, and digital services.
  • ·Focus on the Quintuple Aim: better patient outcomes, better patient experiences, better care team experiences, lower total cost of care, and expanded access.
  • ·Transitioning to a direct sales model in Italy, Spain, and Portugal following the acquisition of distribution businesses.

  Capital allocation

  As of June 30, 2026, the Board had authorized an aggregate of $17.4 billion for the common stock repurchase program, with $5.0 billion added in April 2026. Approximately $4.7 billion remained available. During the first six months of 2026, the Company repurchased 3.2 million shares for $1,506.5 million.

  Extracted by deepseek-v4-flash · Jul 23, 2026

• 8-KJul 16, 2026Item 2.02,9.01

  Source ↗

  This 8-K filing solely reports the issuance of a press release on July 16, 2026, regarding Intuitive Surgical's Q2 2026 financial results. The actual press release (Exhibit 99.1) is not included in the provided text, so no financial figures, management commentary, guidance, or forward-looking statements are available for extraction.

  Show extraction ▾Hide extraction ▴

  Extracted by deepseek-v4-flash · Jul 23, 2026

• 10-QApr 22, 2026

  Source ↗

  Intuitive Surgical reported a strong Q1 2026 with 23% revenue growth, driven by broad-based strength across instruments, systems, and services, and a 48% increase in operating income. The company completed a $533 million acquisition to take direct control of distribution in key European markets, and its installed base of da Vinci 5 systems reached 1,464. However, tariff costs of $28 million and ongoing macroeconomic uncertainty pose headwinds; management noted that future tariff changes could materially impact results. The balance sheet remains debt-free, and the company returned $1.1 billion to shareholders via buybacks while still having $0.6 billion in authorization remaining. Investors should monitor the tariff situation, hospital spending trends, and the integration of the European distribution acquisition.

  Show extraction ▾Hide extraction ▴

  MD&A highlights

  • ·Total revenue increased 23% to $2,770.8 million for Q1 2026, driven by growth in instruments and accessories, systems, and service revenue.
  • ·Gross profit rose 26% to $1,830.5 million, and income from operations increased 48% to $855.3 million.
  • ·Net income attributable to Intuitive was $821.5 million ($2.28 diluted EPS) vs. $698.4 million ($1.92 diluted EPS) in Q1 2025.
  • ·Completed acquisition of da Vinci and Ion distribution businesses in Italy, Spain, Portugal, and associated territories for approximately $533.1 million.
  • ·Tariffs and other trade measures recognized in cost of revenue were approximately $28 million during Q1 2026.
  • ·Installed base of da Vinci 5 surgical systems reached 1,464 as of March 31, 2026.

  Backlog

  Remaining performance obligations were $3.3 billion as of March 31, 2026, with approximately half expected to be recognized in the next 12 months and the remainder over terms generally up to 5 years.

  Key risks

  • ·Macroeconomic and geopolitical factors, including tariffs, inflation, interest rates, and supply chain disruptions, could materially adversely affect results.
  • ·U.S. tariffs on imports from Mexico (where most instruments are manufactured), Germany (endoscopes), and China, plus reciprocal measures, create uncertainty and may increase costs.
  • ·Hospitals face significant financial pressure from rising operating costs and elevated interest rates, potentially reducing procedure volumes and system placements.
  • ·Legal proceedings, including antitrust and product liability litigation, could result in material adverse outcomes.
  • ·Reliance on sole- and single-sourced suppliers poses supply continuity risks.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  Future changes to tariff rates and the imposition of new tariffs by the U.S. and/or other countries could result in a material impact to our results of operations.

  Strategic priorities

  • ·Advance the Quintuple Aim: better patient outcomes, better patient experiences, better care team experiences, lower cost of care, and expanded access to minimally invasive care.
  • ·Expand adoption of da Vinci 5, Ion, and da Vinci SP surgical systems through regulatory clearances and new indications.
  • ·Transition to direct distribution model in European markets following the acquisition of distribution businesses in Italy, Spain, and Portugal.
  • ·Continue investment in digital portfolio, including Advanced Insights Suite and learning technologies.

  Capital allocation

  The Company repurchased 2.3 million shares for $1,127.5 million during Q1 2026, leaving approximately $0.6 billion remaining under the $13.0 billion authorized repurchase program. The Board increased authorization by $4.0 billion in May 2025.

  Extracted by deepseek-v4-flash · Jul 23, 2026

• 8-KApr 21, 2026Item 2.02,9.01unprocessed

  Source ↗

  Facts ingested; qualitative extraction pending.

• 10-KFeb 03, 2026

  Source ↗

  Intuitive Surgical's 2025 10-K emphasizes its leadership in robotic-assisted surgery and endoluminal diagnostics, with a strong focus on the Quintuple Aim to drive clinical and economic value. The company highlights competitive pressures from established and emerging players, risks from international operations (including tariffs and geopolitical tensions), and reliance on sole- and single-sourced suppliers. Management expresses confidence in its ability to leverage technological advances for future growth, but the filing provides no specific financial guidance, debt commentary, or backlog data. Capital allocation and capex plans are not detailed beyond existing manufacturing footprint and ongoing construction risks.

  Show extraction ▾Hide extraction ▴

  Key risks

  • ·Our commercial landscape is highly competitive, and customers may choose our competitors' products or services or may not accept robotic-assisted medical procedures.
  • ·We are subject to a variety of risks due to our operations outside of the U.S.
  • ·We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators.
  • ·We offer usage-based arrangements, including alternative capital acquisition approaches; as a result, we are exposed to an increased risk of losses of revenue and increased credit risk.
  • ·Our reliance on sole- and single-sourced suppliers and ability to purchase at acceptable prices a sufficient supply of materials could harm our ability to meet product demand.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  We believe that we are well-positioned to synthesize scientific and technological advances in biology, computing, imaging, algorithms, and robotics to deliver meaningful and measurable value to all of our stakeholders.

  Strategic priorities

  • ·Align goals through the Quintuple Aim: enabling better patient outcomes, improving patient and care team experience, expanding access to care, and lowering total cost to treat per patient episode.
  • ·Provide hospitals with attractive clinical and economical solutions across the spectrum of procedure complexity.
  • ·Focus development efforts on procedures where products bring the highest patient, surgeon, and hospital value.

  Extracted by deepseek-v4-flash · Jul 23, 2026

• neutrallow magnitudemedium-termtrade-presstoday

  J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive

  Auto-collected from MedTech Dive; awaiting human review.

  Source ↗

  ApproveReject